- •Leucocytoclastic vasculitis is associated with immune-checkpoint inhibitors therapy.
- •Thrombocytopenic purpura is the main differential diagnosis.
- •Steroids and hydroxychloroquine are an effective and safe therapy.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Internal Medicine
- The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer. 2012; 12: 252-264
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.Ann Oncol. 2015; 26: 1824-1829
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Ann Oncol. 2015; 26 ([mdv383])
- Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.Autoimmun Rev. 2018; 17: 284-289
- Vasculitis associated with immune checkpoint inhibitors - A systematic review.Clin Rheumatol. 2018;
- Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma.Ann Oncol. 2017; 28: 1675-1676